source
- Claret says it latest fund will have larger focus on European life sciencesEuropean firm Claret Capital Partners has raised €575 million in its latest round, dubbed Fund IV, and a sizable portion will be lent out to local biotech companies and manufacturers. Roughly one t…Endpoints · 20m ago↗ source
- Novartis and Ionis's pelacarsen fails to cut heart events despite lowering Lp(a) levelsNovartis and Ionis reported that pelacarsen, an RNA therapy aimed at lowering lipoprotein(a), did not reduce major cardiovascular events in a Phase 3 trial of over 8,000 patients. The study compare…